Patent · US Active

Identification of a JAK2 mutation in polycythemia vera

US10364430B2 · kind B2 · utility

0Cited by
7References
3Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJan 27, 2014
Grant dateJul 30, 2019
Priority date
Expiry dateJan 27, 2034

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2500/04
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.